Regeneron will provide the U.S. with 300,000 doses of its newly authorized Covid-19 antibody treatment by early January, CEO Dr. Leonard Schleifer said.
U.S. stock futures rose Monday, supported by positive Covid-19 vaccine data from AstraZeneca and FDA emergency approval for Regeneron's antibody treatment.
With Thanksgiving travel curbed as a result of the CDC's warning about heightened Covid-19 risk, two traders gauge the impact on the underlying stocks.
The medicine, CD24Fc, was shown to reduce the risk of respiratory failure or death by more than 50% in patients hospitalized with Covid and requiring oxygen
Best Buy and Dollar Tree's stocks are in opposite positions heading into the companies' earnings reports this week, Piper Sandler's Craig Johnson says.
Promising developments on the vaccine front have sparked optimism that the pandemic's end is in sight. Many market sectors may benefit; others may not.
President Trump did not participate in a virtual G-20 event on pandemic preparedness, even as Covid-19 infections surge and break daily records across the U.S.
Operation Warp Speed chief adviser Dr. Moncef Slaoui has "been informed" not to share vaccine information outside of the Trump administration, he tells NBC's Meet the Press on Sunday.
Regeneron's therapy is part of a class of treatments known as monoclonal antibodies, which are made to act as immune cells that scientists hope can fight infections.
As GM profitably guides itself through the coronavirus pandemic, Wall Street is paying more attention to its bottom line than unprofitable mobility efforts.